Catalog No.
Product Name
Application
Product Information
Citations
-
γ secretase Modulator
PF-06442609 is an orally active γ secretase modulator that effectively inhibits amyloid-beta (Aβ42) production with an IC50 of 6 nM. This compound demonstrates excellent brain penetration, making it suitable for research in neurodegenerative disease models, particularly Alzheimer's disease. Its modulatory effects on γ secretase activity provide valuable insights into the mechanistic understanding of amyloid plaque formation and associated pathologies. -
γ-secretase Inhibitor
LY-411575 (isomer 2) is a potent inhibitor of γ-secretase, an enzyme involved in the cleavage of amyloid precursor protein and a key player in the pathogenesis of Alzheimer's disease. This compound has been shown to effectively reduce the production of amyloid-beta peptides, making it valuable for research into therapeutic strategies for neurodegenerative disorders. Its selective inhibition of γ-secretase also facilitates the study of its role in cellular signaling and development. -
γ-secretase Inhibitor
GSI-136 is a potent inhibitor of γ-secretase, exhibiting an IC50 of 3 nM. This compound effectively reduces Aβ40 levels in diethylamine-extracted brain homogenates from C57BL/6 mice in a dose-dependent manner. GSI-136 serves as a valuable tool in medicinal chemistry and Alzheimer’s disease research, aiding in the exploration of therapeutic strategies targeting amyloid-beta production. -
γ-secretase
LY-411575 (isomer 1) is a potent γ-secretase inhibitor that selectively modulates the enzyme's activity. This compound is primarily utilized in the investigation of Alzheimer’s disease pathogenesis by reducing the production of harmful amyloid-beta peptides. Its mechanism of action allows for a deeper understanding of γ-secretase's role in cellular signaling and pathology, making it a valuable tool in neurological research. -
γ-secretase Inhibitor
LY-411575 (isomer 3) is a potent inhibitor of γ-secretase, an enzyme complex involved in the proteolytic processing of various transmembrane proteins, including amyloid precursor protein (APP). This compound is utilized in research studying Alzheimer's disease and other conditions associated with aberrant Notch signaling. Its ability to modulate γ-secretase activity makes it a valuable tool for investigating the therapeutic potential of targeting this pathway. -
γ-secretase Inhibitor
ELN318463 racemate is a selective γ-secretase inhibitor targeting the amyloid precursor protein (APP). It demonstrates differential inhibition of presenilin (PS1) and PS2-comprised γ-secretase, with EC50 values of 12 nM for PS1 and 656 nM for PS2, indicating a 51-fold selectivity for PS1. This compound is useful in research applications focused on Alzheimer's disease and the modulation of amyloid beta peptide production. -
AChE/IL-6 Inhibitor
Y13g is a potent dual inhibitor of acetylcholinesterase (AChE) and interleukin-6 (IL-6). By targeting these pathways, Y13g demonstrates significant potential in addressing memory deficits associated with Alzheimer’s Disease. In preclinical studies, Y13g effectively reverses memory impairment induced by STZ and exhibits histopathological profiles akin to those of healthy specimens, making it a valuable tool for research in neurodegeneration and inflammatory responses.
-
BChE/p38-α MAPK Inhibitor
BChE/p38-α MAPK-IN-1 is a selective dual inhibitor targeting human butyrylcholinesterase (BChE) with an IC50 of 772 nM and p38 α MAPK with an IC50 of 191 nM. This compound significantly reduces the production of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α in cellular models. BChE/p38-α MAPK-IN-1 demonstrates the potential to ameliorate cognitive impairments induced by scopolamine and alleviate spatial learning deficits in LPS-treated mice, making it a valuable tool for studying Alzheimer's disease by addressing cholinergic deficits and neuroinflammation. -
α7nAChR Activator
Lemairamin, an α7nAChR activator, is a hydroxylamine compound derived from the pericarps of Zanthoxylum species. This compound is known to stimulate the expression of anti-inflammatory cytokine IL-10 and proopiomelanocortin (POMC), while concurrently reducing Akt activity. Lemairamin has demonstrated efficacy in attenuating dextran sulfate sodium (DSS)-induced intestinal inflammation and alleviating pain hypersensitivity, making it a valuable reagent for research in inflammation and pain modulation. -
P2Y14R Antagonist
P2Y14R Antagonist 4 is a potent oral antagonist of the P2Y14 receptor, exhibiting an IC50 value of 5.6 nM, indicating high binding affinity. This compound demonstrates anti-inflammatory activity by effectively reducing the release of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α, in response to LPS stimulation. P2Y14R Antagonist 4 is valuable for research applications in inflammation and immune response modulation. -
P2 receptor/NAADP receptor Antagonist
PPADS is a reversible competitive antagonist of P2X receptors, specifically targeting P2X1 and P2X3, with IC50 values of 68 nM and 214 nM, respectively. It demonstrates significant anti-nociceptive effects in mouse models of neuropathic pain and inhibits pro-inflammatory cytokines such as IL-1β and IL-6, as well as nitric oxide synthases. Additionally, PPADS effectively blocks ATP-mediated inward currents in recombinant rat P2X receptors and reduces contractions in rabbit bladder detrusor muscle induced by purinergic nerve stimulation. This compound is valuable for research on neuropathic pain mechanisms and related therapeutic interventions. -
P2X7R Selective Allosteric Antagonist
SMW139 is a selective allosteric antagonist of the P2X7 receptor, demonstrating a Ki value of 32 nM for human P2X7R. This compound exhibits potential in modulating inflammatory responses and has applications in research related to Alzheimer's disease and multiple sclerosis. With a half-life of 47 minutes in rat liver microsomes, SMW139 serves as a valuable tool for investigating the therapeutic effects on P2X7R-mediated pathways. -
AChE/ACP/ALP Inhibitor
Trimyristin is a potent inhibitor of acetylcholinesterase (AChE) as well as acid and alkaline phosphatase (ACP/ALP). It has demonstrated significant inhibitory effects on AChE, ACP, and ALP activities in the nervous tissue of Lymnaea acuminata, with IC50 values of 0.11 mM, 0.16 mM, and 0.18 mM, respectively. This compound is valuable for research applications focused on neurological pathways and enzyme activity modulation. -
CaMKP/CaMKP-N Inhibitor
CaMKP Inhibitor Sodium targets Ca2+/neutral protein-dependent protein kinase (CaMKP) and its nuclear variant (CaMKP-N), exhibiting IC50 values of 6.4 μM and 6.6 μM, respectively. This compound suppresses CaMKP-mediated phospho-CaMKI hydrolysis while leaving protein phosphatases PP2C and calcineurin unaffected. CaMKP plays a critical role in various cellular processes involving serine/threonine phosphorylation, making this inhibitor valuable for research into calcium-dependent signaling pathways and protein regulation. -
Stable Isotope
Trimyristin-d15 is a deuterium-labeled derivative of Trimyristin, a naturally occurring compound extracted from Myristica fragrans. This reagent effectively inhibits acetylcholinesterase (AChE), as well as acid and alkaline phosphatase (ACP/ALP) activities in the nervous tissue of Lymnaea acuminata, with IC50 values of 0.11 mM, 0.16 mM, and 0.18 mM, respectively. Trimyristin-d15 serves as a valuable tool for biochemical research and enzyme activity studies, particularly in exploring the mechanisms of neurotoxicity and molluscicidal action. -
α4β2 nAChR Agonist
TC-2559 free base is an agonist of the α4β2 nicotinic acetylcholine receptor (nAChR), demonstrating an EC50 value of 0.18 μM. It exhibits reduced potency on β4-containing nAChR subtypes, such as α2β4, α4β4, and α3β4, with EC50 values between 10-30 µM. Research indicates that TC-2559 enhances dopamine neuron activity in the ventral tegmental area, which may influence excitability and aggression. Additionally, it possesses anti-inflammatory effects via STAT3 inhibition, proving beneficial in models of mechanical allodynia and cognitive deficits. This compound is useful for investigations into nerve pain and related neurological conditions. -
AChE Inhibitor
Propoxur is a reversible competitive inhibitor of acetylcholinesterase (AChE) that effectively penetrates the blood-brain barrier. This compound induces neurotoxicity by inhibiting AChE activity, resulting in the accumulation of acetylcholine, thereby causing neurological dysfunction. In addition, Propoxur promotes MMP-2 expression and enhances tumor cell migration and invasion through the generation of reactive oxygen species (ROS) and the activation of the ERK/Nrf2 signaling pathway. It is also utilized as a carbamate insecticide for managing pests in turf, forestry, and household environments. -
CaMK Substrate
Syntide 2 is a substrate peptide for calcium/calmodulin-dependent protein kinase II (CaMKII) that demonstrates selective inhibition of the gibberellin (GA) signaling pathway. By targeting this pathway, Syntide 2 facilitates the investigation of mechanisms underlying plant hormone responses while preserving the activity of other regulatory events, such as those mediated by abscisic acid. This reagent is valuable for studies related to cellular signaling and hormone regulation in plant biology. -
CaMKII Inhibitor
Autocamtide-2-related inhibitory peptide is a selective inhibitor of Calcium/Calmodulin-dependent protein kinase II (CaMKII), exhibiting an IC50 value of 40 nM. This peptide effectively modulates CaMKII activity, making it a valuable tool for studying calcium signaling pathways and their implications in various physiological and pathological processes. Its high specificity and potency simplify the investigation of CaMKII-related mechanisms in cellular signaling research. -
COX Inhibitor
Indomethacin farnesil is a prodrug of indomethacin, primarily targeting cyclooxygenase (COX) enzymes. This potent, blood-brain barrier-permeable inhibitor exhibits nonselective activity against COX-1 and COX-2, with IC50 values of 18 nM and 26 nM, respectively. Indomethacin farnesil has been shown to disrupt autophagic flux by impairing lysosomal function, making it useful for investigating inflammatory pathways and autophagy-related processes in research applications. -
Sesquiterpene Lactone
Lactupicrin, a sesquiterpene lactone, primarily targets acetylcholinesterase (AChE), exhibiting an inhibitory activity with an IC50 of 150.3 μM. This compound demonstrates notable analgesic, sedative, and antimalarial effects, alongside its atheroprotective properties. Lactupicrin is an orally active bitter compound, making it valuable for research applications focused on neuropharmacology and cardiovascular health. -
GABA(A) Receptor Antagonist/σ1 Receptor Agonist
Dehydroepiandrosterone sulfate (DHEA sulfate) functions as a GABA(A) receptor antagonist and a σ1 receptor agonist. This neurosteroid, primarily secreted by the adrenal gland, is capable of partially penetrating the blood-brain barrier. It inhibits GABA(A) receptor-mediated chloride influx while enhancing NMDA receptor activity via σ1 receptor interaction, displaying anti-inflammatory and antidepressant properties. DHEA sulfate is relevant for research in neuroprotection, depression, post-traumatic stress disorder (PTSD), and Alzheimer’s disease, and may serve as a biomarker for cardiovascular disease mortality due to its correlation with mortality rates. -
GABA(A) Receptor Antagonist/σ1 Receptor Agonist
Dehydroepiandrosterone sulfate sodium (DHEA sulfate) primarily acts as a non-competitive GABA(A) receptor antagonist and σ1 receptor agonist. This neurosteroid, predominantly secreted by the adrenal gland, has demonstrated significant biological activities, including enhancing NMDA receptor function and exerting anti-inflammatory and antidepressant effects. DHEA sulfate sodium can penetrate the blood-brain barrier, making it valuable in research applications related to neuroprotection, neurite growth regulation, and neuropsychiatric disorders such as depression, post-traumatic stress disorder (PTSD), and Alzheimer's disease. Additionally, it may serve as a biomarker for cardiovascular disease mortality, with its levels inversely correlated with mortality rates. -
COX-2 Inhibitor/PPAR-γ Activator
Zaltoprofen sulfoxide is a selective COX-2 inhibitor with an IC50 of 45.38 nM, as well as a PPAR-γ activator. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, making it a valuable tool in the study of inflammation and acute lung injury models. It is particularly relevant for research focused on LPS-induced acute lung injury. -
AChE/BChE Inhibitor
Epiberberine chloride is an alkaloid derived from Coptis chinensis, functioning primarily as a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 1.07 μM and 6.03 μM, respectively. This compound also serves as a non-competitive inhibitor of BACE1, with an IC50 of 8.55 μM. In addition to its cholinesterase inhibition, Epiberberine chloride exhibits antioxidant properties, demonstrated by its ability to scavenge peroxynitrite (IC50 of 16.83 μM), suggesting a potential protective role in Alzheimer’s disease research. Furthermore, it inhibits the early differentiation of 3T3-L1 preadipocytes and downregulates key signaling pathways, indicating its relevance in studies on diabetes. -
COX-2 Inhibitor
Hexahydrocurcumin is a selective, orally active inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant potential in anti-inflammatory applications. As one of the primary metabolites of curcumin, it exhibits antioxidant and anticancer properties, making it relevant for research in various therapeutic areas. Its selectivity towards COX-2 over COX-1 highlights its potential for minimizing gastrointestinal side effects often associated with non-steroidal anti-inflammatory drugs (NSAIDs). -
Aβ/tau Aggregation Inhibitor
Aβ/tau aggregation-IN-4 is a potent inhibitor of amyloid-beta (Aβ) and tau aggregation. It effectively promotes the degradation of Aβ40 and Aβ42 with IC50 values of 2.151 μM and 3.622 μM, respectively. Additionally, Aβ/tau aggregation-IN-4 exhibits selective inhibition of acetylcholinesterase (AChE) with an IC50 of 5.56 μM, and inhibits monoamine oxidase A (MAO-A) and B (MAO-B) with IC50 values of 0.59 μM and 0.09 μM, respectively. This compound also reduces intracellular reactive oxygen species (ROS) levels, making it a valuable tool in Alzheimer's disease research. -
COX-2 Inhibitor
COX-2-IN-65 is a selective inhibitor of cyclooxygenase-2 (COX-2) with a reported IC50 of 10.24 μM. This compound exhibits antibacterial activity against Staphylococcus aureus and Escherichia coli, while also scavenging reactive oxygen species (ROS). COX-2-IN-65 is valuable for research applications focused on bacterial infections and inflammation pathways. -
MAO-B Inhibitor
MAO-B-IN-7 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase (AChE), demonstrating IC50 values of 41 nM for human AChE, 87 nM for electric eel AChE, and 0.3 μM for MAO-B. This compound is notable for its ability to penetrate the blood-brain barrier, making it suitable for central nervous system research. MAO-B-IN-7 has been shown to mitigate oxidative stress and neuroinflammation, supporting its potential applications in neurodegenerative disease studies. -
Insecticide
Methiocarb is an orally active carbamate insecticide primarily targeting acetylcholinesterase to induce cholinergic excitation. It exhibits dose-dependent toxic effects on various organisms, including notable oxidative stress through lipid peroxidation in liver, kidney, brain, and testicular tissues, while also altering reduced glutathione levels via reactive oxygen species generation. This compound is utilized for agricultural pest control and serves as a valuable research tool for studying oxidative stress-related cellular damage in mammalian models. -
NMDA Receptor Inhibitor
MN-05 is a dual neuroprotective and vasodilatory inhibitor of the NMDA receptor. By blocking calcium influx, it reduces free radical production and preserves mitochondrial membrane potential in cortical neurons exposed to glutamate. Additionally, MN-05 exhibits vasodilatory effects by dilating aortic rings in response to phenylephrine-induced contraction. This compound demonstrates protective properties against glutamate-induced neuronal injury in vitro, making it valuable for research in neurodegenerative diseases. -
Diallyl Tetrasulfide
Diallyl tetrasulfide functions as an antioxidant, primarily by mitigating cadmium-induced neurotoxicity and oxidative liver injury. This compound has demonstrated the ability to regulate acetylcholinesterase and adenosine triphosphatase activities, as well as protect against oxidative stress in the brain and liver tissues of animal models. Diallyl tetrasulfide also inhibits lipid peroxidation and reduces reactive oxygen species (ROS) production, thereby enhancing cell viability and decreasing apoptosis. It is a valuable reagent for studies focused on cadmium-induced cellular damage and neuroprotection. -
mAChR Ligand
Azacyclonol hydrochloride is a selective ligand for the M3 muscarinic acetylcholine receptor, demonstrating significant inhibition of proliferation in androgen-refractory cancer cell lines, including DU145 and PC-3. This compound exhibits notable anticancer activity, particularly in A549 human lung cancer cells, by inhibiting NOX-derived reactive oxygen species. Additionally, Azacyclonol hydrochloride has shown antitumor effects in xenografted chorioallantoic membrane models. Beyond its anticancer applications, it is also explored for its potential in the treatment of chronic schizophrenia. -
Pancreatic Lipase/Acetylcholinesterase/Glutamic-oxaloacetic Transaminase 1/Alpha-glucosidase Inhibitor
Aspulvinone H is a potent inhibitor targeting pancreatic lipase, acetylcholinesterase, glutamic-oxaloacetic transaminase 1 (GOT1), and α-glucosidase, with IC50 values of 25.95 μM, 47.06 μM, 5.91/6.91 μM, and 4.6 μM, respectively. It demonstrates key biological activities including inhibition of cancer cell proliferation, disruption of glutamine metabolism, and induction of apoptosis in cancer cells. Additionally, Aspulvinone H lowers postprandial blood glucose levels in mice and exhibits antibacterial properties against Staphylococcus aureus. This compound is suitable for research into pancreatic ductal adenocarcinoma, diabetes management, and infectious diseases caused by Staphylococcus aureus. -
Cysteine Analog
D-Ribose-L-cysteine is an orally active cysteine analog that enhances intracellular glutathione (GSH) biosynthesis, thereby improving cellular antioxidant capacity. This compound exhibits memory-enhancing effects and can reverse Scopolamine-induced memory impairment through the inhibition of oxidative stress and acetylcholinesterase (AChE) activity. D-Ribose-L-cysteine is valuable for research on neurodegenerative and cardiovascular diseases, providing insights into therapeutic strategies for these conditions. -
CaMK II Inhibitor
KN-93 hydrochloride is a potent and selective inhibitor of calmodulin-dependent kinase type II (CaMKII), functioning through a reversible and competitive mechanism with an inhibition constant (Ki) of 370 nM. This compound is widely utilized in research involving calcium signaling pathways and neuronal activity modulation. Its ability to inhibit CaMKII makes it valuable for studies investigating cardiac function, neurodegenerative diseases, and synaptic plasticity. -
TFEB Activator
TFEB Activator 2 is a potent oral compound that effectively crosses the blood-brain barrier, targeting the dopamine transporter (DAT). It promotes TFEB nuclear translocation and enhances lysosome biogenesis through modulation of the DAT-CDK9-TFEB signaling pathway. With demonstrated neuroprotective properties, this reagent is valuable for research applications related to Alzheimer's disease and other neurodegenerative conditions. -
CaMKII Substrate
Autocamtide 2 is a selective peptide substrate for calcium/calmodulin-dependent protein kinase II (CaMKII). This reagent is primarily utilized in assays to measure CaMKII activity, providing valuable insights into cellular signaling pathways influenced by calcium. Its specificity ensures reliable results in research applications involving calcium-dependent processes. -
CaMKII Inhibitor
Autocamtide-2-related inhibitory peptide, myristoylated is a potent and selective inhibitor of CaMKII, exhibiting an IC50 of 40 nM. This peptide is used in research applications to investigate the regulatory mechanisms of calcium-dependent signaling pathways. Its myristoylation enhances its membrane permeability, facilitating in vivo studies of CaMKII activity and function in various cellular contexts. -
Cholinesterase (ChE) Inhibitor
Sophoflavescenol is a prenylated flavonol that acts as a cholinesterase (ChE) inhibitor, demonstrating potent inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values of 10.98 μM and 8.21 μM, respectively. Additionally, it shows significant inhibition of other enzymes, including RLAR, HRAR, and BACE1. This compound is primarily utilized in research related to neurodegenerative diseases and cognitive function enhancement, making it a valuable reagent for studying cholinergic pathways. -
COX Inhibitor
Aspirin DL-lysine is a lysine-conjugated derivative of aspirin that functions primarily as a cyclooxygenase (COX) inhibitor. This compound effectively inhibits the synthesis of thromboxane A2 (TXA2) in platelets, leading to a reduction in platelet activation and aggregation. Aspirin DL-lysine is valuable for research applications focused on thrombin generation, particularly in clinical studies involving unstable angina pectoris. -
p38α MAPK/BChE Inhibitor
ARRY-371797 is a potent and orally bioavailable inhibitor of p38α MAPK and butyrylcholinesterase (BChE), demonstrating IC50 values of 12.0 µM for p38α MAPK and 0.13 µM for BChE, with minimal activity against human acetylcholinesterase (hAChE). This compound shows promise for research applications in Alzheimer’s disease, particularly in the context of neuroinflammation and cholinergic system modulation. -
P2Y14 Receptor Agonist
MRS2690 is a selective agonist of the P2Y14 receptor, primarily known for its role in the inhibition of adenylyl cyclase activity, which leads to a reduction in intracellular cAMP levels. This compound mediates concentration-dependent vasoconstriction in porcine coronary arteries and induces intracellular calcium mobilization. Additionally, MRS2690 activates p38 MAPK and stimulates [35S]GTPγS binding in RBL-2H3 cell membranes. It also enhances β-hexosaminidase release in response to antigen and complement activation, making it a valuable tool for research in ischemic heart disease. -
CaMKK2 Inhibitor
CC-3240 is a highly selective inhibitor of CaMKK2, exhibiting a potent inhibitory effect with an IC50 of 9 nM. This molecular glue degrader, developed from CC-8977, effectively disrupts the function of CaMKK2, making it a valuable tool for investigations into calcium and calcium/calmodulin-dependent signaling pathways. CC-3240 is particularly useful in research applications aimed at exploring the role of CaMKK2 in cellular processes and disease states. -
COX-2/Carbonic Anhydrase Inhibitor
Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation. -
AChE/hCA Inhibitor
AChE/hCA I-IN-1 is a selective inhibitor of acetylcholinesterase (AChE) and human carbonic anhydrases (hCA I and hCA II). It demonstrates potent inhibition with IC50 values of 302 nM for AChE, 265 nM for hCA I, and 283 nM for hCA II. This compound is valuable for research applications exploring neurodegenerative disorders and the regulation of physiological pH balance. -
AChE/hCA Inhibitor
AChE/hCA I/II-IN-1 is a potent inhibitor of acetylcholinesterase (AChE) and human carbonic anhydrases I and II (hCA I/II), demonstrating IC50 values of 22.21 nM for AChE, and 60.79 nM and 66.64 nM for hCA I and II, respectively. This compound is valuable for research applications related to glaucoma, Alzheimer’s disease, and diabetes, providing insights into the modulation of these critical enzymatic targets. -
COX-2 Inhibitor
COX-2-IN-30 is a benzenesulfonamide derivative that functions as a potent selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 49 nM and also inhibits 5-lipoxygenase (5-LOX) with an IC50 of 2.4 μM. Additionally, it affects human carbonic anhydrase isoforms IX and XII, displaying nanomolar Ki values. This compound demonstrates significant analgesic and anti-inflammatory properties while maintaining a favorable gastrointestinal safety profile, making it useful for research in inflammation, pain relief, and related gastrointestinal studies. -
hCA I/II Inhibitor
hCAI/II-IN-5 is a potent inhibitor of human carbonic anhydrase isoenzymes I and II, exhibiting IC50 values of 37.88 nM and 45.23 nM, respectively. Additionally, it demonstrates inhibitory activity against α-Glycosidase and acetylcholinesterase (AChE) with IC50 values of 48.98 nM and 420.14 nM. This compound is valuable for research applications in various diseases, including diabetes, Alzheimer's disease, heart failure, ulcers, and epilepsy. -
CA/ChE Inhibitor
hCA I-IN-4 is an inhibitor of carbonic anhydrase (CA) and cholinesterase (ChE), demonstrating potent inhibitory activity against hCA I, hCA II, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) with Ki values of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nM, respectively. This compound also exhibits cytotoxic effects in BT-549 cancer cells, with an IC50 value of 16.59 μM. hCA I-IN-4 is valuable for research involving enzyme regulation and cancer therapeutics.
